Clinical Trials and Therapeutics
Use of antisense oligonucleotide in Progressive supranuclear palsy
Phase 1 clinical trial funded by Novartis
About the project:
Phase 1 first in human clinical trial in patients with progressive supranuclear palsy.
Dr Boyd Ghosh Consultant Neurologist
Key iDeAC expertise: